Education
About Us
Working with TipRanks
Follow Us
Mountain Valley MD (TSE:MVMD)
:MVMD
MVMD Stock Chart & Stats
C$0.02
<C$0.01(20.00%)
At close: 4:00 PM EST
C$0.02
<C$0.01(20.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.04
Previous CloseN/A
Volume2.00K
Average Volume (3M)205.59K
Market Cap
C$5.29M
Enterprise ValueC$3.05M
Total Cash (Recent Filing)C$1.72M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,354,950
10 Day Avg. Volume152,980
30 Day Avg. Volume205,595
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.44
Price to Sales (P/S)177.77
P/FCF Ratio-2.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Near-zero DebtNear-zero reported debt materially reduces interest burden and financial distress risk over the medium term. With minimal leverage, the company has greater optionality to prioritize R&D or business development over debt servicing, preserving strategic flexibility while it pursues commercialization.
Improving Gross Profit / Unit EconomicsA return to positive gross profit suggests product-level margins can cover direct costs, a prerequisite for scalable profitability. If sustained, this improvement supports future operating leverage: reduced need for price support and a clearer path to narrowing operating losses as fixed costs are managed.
Industry Exposure: Specialty & Generic DrugsPositioning in specialty and generic pharmaceuticals offers structural demand and persistent market need. Regulatory barriers and manufacturing requirements can create entry frictions, enabling established players to capture steady revenue streams if the company can stabilize operations and commercial execution.
Bears Say
Persistent Negative Cash GenerationConsistent negative operating and free cash flow erodes runway and forces repeated external financing. Over months, this limits ability to fund R&D, scale commercialization, or withstand setbacks without dilutive equity raises, constraining long-term strategic options and investor returns.
Eroding Equity Cushion / Capital BaseA steep decline in shareholders' equity reflects cumulative losses and weak capital retention, leaving a thin buffer for operational shocks. This degradation increases the probability of future dilution, reduces credibility with lenders/partners, and impairs the firm's ability to pursue sustained growth investments.
Minimal, Declining And Volatile RevenueExtremely small and falling revenue undermines scale economies and market validation. With limited sales, fixed operating costs dominate, making margin improvement difficult and heightening reliance on financing. Persistent top-line weakness challenges long-term viability absent clear commercial traction.
Mountain Valley MD News
MVMD FAQ
What was Mountain Valley MD’s price range in the past 12 months?
Mountain Valley MD lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Mountain Valley MD’s market cap?
Mountain Valley MD’s market cap is C$5.29M.
When is Mountain Valley MD’s upcoming earnings report date?
Mountain Valley MD’s upcoming earnings report date is Mar 04, 2026 which is in 27 days.
How were Mountain Valley MD’s earnings last quarter?
Mountain Valley MD released its earnings results on Dec 02, 2025. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Mountain Valley MD overvalued?
According to Wall Street analysts Mountain Valley MD’s price is currently Overvalued.
Does Mountain Valley MD pay dividends?
Mountain Valley MD does not currently pay dividends.
What is Mountain Valley MD’s EPS estimate?
Mountain Valley MD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mountain Valley MD have?
Mountain Valley MD has 352,354,950 shares outstanding.
What happened to Mountain Valley MD’s price movement after its last earnings report?
Mountain Valley MD reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mountain Valley MD?
Currently, no hedge funds are holding shares in TSE:MVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mountain Valley MD
Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.
Technical Analysis
Ayurcann Holdings Corp.
―
Revive Therapeutics
―
PharmaCielo
―
CanadaBis Capital
―
Lobe Sciences
―
Options Prices
Currently, No data available
---